James M. Frates - 09 Nov 2026 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
12 Nov 2026, 16:00:08 UTC
Prior SEC filing
14 Sep 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Joshua B. Cohen, as Attorney in Fact
Filing notes and source

Key filing fact

James M. Frates filed Form 4 for Amylyx Pharmaceuticals, Inc. (AMLX) on 12 Nov 2026.

Key facts

  • This page summarizes James M. Frates's Form 4 filing for Amylyx Pharmaceuticals, Inc. (AMLX).
  • 8 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 12 Nov 2026, 16:00.

Change

  • Previous filing in this sequence was filed on 14 Sep 2026.
  • Current net transaction value: -$1,207,742.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001235598 Primary reporting owner

FRATES JAMES M

Relationship
Chief Financial Officer
Address
C/O AMYLYX PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Signature date
12 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMLX transaction

Common Stock

Options Exercise

Transaction value
Shares
+20,000
Change %
+8.6%
Price
$6.88*
Shares after
253,625
Date
09 Nov 2026
Ownership
Direct
Footnotes
F1
AMLX transaction

Common Stock

Sale

Transaction value
-$226,293
Shares
-7,700
Change %
-3%
Price
$29.39
Shares after
245,925
Date
09 Nov 2026
Ownership
Direct
Footnotes
F1, F2
AMLX transaction

Common Stock

Sale

Transaction value
-$370,359
Shares
-12,300
Change %
-5%
Price
$30.11
Shares after
233,625
Date
09 Nov 2026
Ownership
Direct
Footnotes
F1, F3
AMLX transaction

Common Stock

Options Exercise

Transaction value
Shares
+20,000
Change %
+8.6%
Price
$6.88*
Shares after
253,625
Date
10 Nov 2026
Ownership
Direct
Footnotes
F1
AMLX transaction

Common Stock

Sale

Transaction value
-$388,108
Shares
-12,800
Change %
-5%
Price
$30.32
Shares after
240,825
Date
10 Nov 2026
Ownership
Direct
Footnotes
F1, F4
AMLX transaction

Common Stock

Sale

Transaction value
-$222,983
Shares
-7,200
Change %
-3%
Price
$30.97
Shares after
233,625
Date
10 Nov 2026
Ownership
Direct
Footnotes
F1, F5
AMLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
100,000
Date
09 Nov 2026
Ownership
By Trust
Footnotes
F6
AMLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
15,459
Date
09 Nov 2026
Ownership
By Trust
Footnotes
F7
AMLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
11,072
Date
09 Nov 2026
Ownership
By Trust
Footnotes
F8
AMLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
40,000
Date
09 Nov 2026
Ownership
By Trust
Footnotes
F9

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMLX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-20,000
Change %
-5.5%
Price
$0.000000*
Shares after
343,835
Date
09 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
20,000
Exercise price
$6.88
Footnotes
F1, F10
AMLX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares
-20,000
Change %
-5.8%
Price
$0.000000*
Shares after
323,835
Date
10 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
20,000
Exercise price
$6.88
Footnotes
F1, F10
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 10 footnotes

Footnote F1

The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 10, 2026.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.81 to $29.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.82 to $30.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.86 to $30.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.905 to $31.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F6

Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Footnote F7

Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Footnote F8

Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Footnote F9

Shares held by the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Footnote F10

This option is fully vested and exercisable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .